Skip to content
Peptide research

VK2735

Also known as Viking 2735
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

VK2735 is a dual GLP-1/GIP receptor agonist for rapid weight loss, marketed as an alternative to GLP-1-only drugs. Early human trials show up to 14.7% weight loss in 13 weeks and high responder rates, but the evidence base is still thin and long-term safety data are lacking. The main risk is gastrointestinal side effects, plus a theoretical thyroid tumor concern. It is not FDA-approved and circulates as unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Rapid and substantial weight loss (up to 14.7% in 13 weeks with no plateau)

    High

    Human randomized trial showed up to 14.7% weight loss at 13 weeks, no plateau.

  • High responder rate — up to 88% of patients achieved 10% or greater weight loss

    Medium

    Phase 2 VENTURE trial: 88% of patients lost 10%+ weight versus 4% on placebo.

  • Durable weight loss maintenance (over 80% of weight loss maintained 7 weeks post-dosing)

    Medium

    Small follow-up subset of trial participants retained most weight loss 7 weeks post-dosing.

Evidence limits

Evidence Level
Moderate-Strong Evidence

VK2735 has completed Phase 1 and Phase 2 trials and is now in Phase 3. The Phase 2 VENTURE trial (n=176) was a randomized, double-blind, placebo-controlled study that met all primary and secondary endpoints with up to 14.7% weight loss in 13 weeks. Results from VENTURE have been published in the journal Obesity. Both Phase 3 VANQUISH trials have completed enrollment; their efficacy and safety results remain pending.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events (nausea, vomiting, GI disturbances)

    High
  • Dehydration (from GI side effects)

    Moderate
  • Limited long-term safety data

    High
  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.